Published online Dec 6, 2020. doi: 10.12998/wjcc.v8.i23.6181
Peer-review started: August 7, 2020
First decision: August 22, 2020
Revised: August 29, 2020
Accepted: September 25, 2020
Article in press: September 25, 2020
Published online: December 6, 2020
Processing time: 119 Days and 3.2 Hours
Coronavirus disease 2019 (COVID-19) severity is classified as asymptomatic, mild, moderate, severe, and critical. Mild cases account for a large percentage of cases in the epidemic and typically exhibit a favorable prognosis. However, a 49%-67% mortality is noted in critical cases. No COVID-19-specific drug has been reported to date, and symptomatic and optimal supportive care, including oxygenation, anti-coinfection treatments, and ventilation, represent the mainstay of treatment for this disease, especially in critical patients.
In the above-mentioned context, we share our experience with the treatment of one critical COVID-19 case and review the relevant literature.
Timely tracheal intubation, reasonable mechanical ventilation support, appropriate anti-infection treatment, and early anticoagulation and immunity support are key factors in the successful treatment of this case.
Core Tip: The mortality of severe coronavirus disease 2019 (COVID-19) patients is high, and no effective antiviral drugs are available now. Therefore, it is important to identify a suitable treatment strategy that is associated with improved prognosis of COVID-19, especially in critically ill patients. Here, we share our experience with the treatment of one critical COVID-19 case. We conclude that timely intubation, reasonable mechanical ventilation support, appropriate anti-infection treatment, early anticoagulation and immune support, and other comprehensive measures may help to reduce the course of disease and patient mortality.